Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.

Details

Ressource 1Download: 29728694_BIB_8FC71E831A84.pdf (824.38 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_8FC71E831A84
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Journal
Leukemia
Author(s)
Sun W., Malvar J., Sposto R., Verma A., Wilkes J.J., Dennis R., Heym K., Laetsch T.W., Widener M., Rheingold S.R., Oesterheld J., Hijiya N., Sulis M.L., Huynh V., Place A.E., Bittencourt H., Hutchinson R., Messinger Y., Chang B., Matloub Y., Ziegler D.S., Gardner R., Cooper T., Ceppi F., Hermiston M., Dalla-Pozza L., Schultz K.R., Gaynon P., Wayne A.S., Whitlock J.A.
ISSN
1476-5551 (Electronic)
ISSN-L
0887-6924
Publication state
Published
Issued date
11/2018
Peer-reviewed
Oui
Volume
32
Number
11
Pages
2316-2325
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.
Keywords
Antineoplastic Agents/therapeutic use, B-Lymphocytes/drug effects, B-Lymphocytes/pathology, Bone Marrow/drug effects, Bone Marrow/pathology, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Male, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/mortality, Neoplasm Recurrence, Local/pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/mortality, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology, Remission Induction/methods, Retrospective Studies, Salvage Therapy/methods
Pubmed
Web of science
Open Access
Yes
Create date
12/05/2018 10:36
Last modification date
26/02/2020 7:26
Usage data